White paper / June 2026

The Launch Decision Architecture

White paperLaunchOperating models

How decisions before launch shape commercial performance. The paper examines launch planning and includes the Launch Reality Report and its supporting dataset.

For teams preparing a launch and reviewing the decisions behind their commercial plan.

Our review of the 25 largest companies' disclosed pipelines identified 96 commercially significant launches planned for 2026, 2027 and 2028. Of those, 61 were planned for 2026. Many would need to reach the same prescribers and compete for their attention.

That makes it important to understand what HCPs need from each interaction. Adding representatives or sending more messages has limited value if the engagement does not help the clinician.

The paper examines decisions made in the 18 months before launch, including how teams plan customer engagement and assign responsibility. It sets out an approach to making those decisions. The accompanying Launch Reality Report compares projected and actual performance for launches between 2020 and 2025, with the supporting dataset available for review.

Key findings

Commercial readiness deserves the same scrutiny as the molecule

The accompanying Launch Reality Report examines 50 anticipated launches from 2020–2025. It classifies 15 as clear misses; 13 of those reached the market but fell short on commercial foundations, while two failed because the science did not deliver. These are findings within the selected sample, not an industry-wide failure rate.

The coming launch wave increases the competition for attention

The pipeline review identified 96 commercially significant launches planned across 2026–2028, including 61 in 2026, among roughly the 25 largest companies. The review covers disclosed plans in the US, Europe, Japan and China; it is a snapshot of expected launches, not a count of completed launches.

Agree how the model will change before the market changes

The framework separates what headquarters fixes, what country teams choose and how the model adapts. A cross-functional Launch Council and shared Launch Cockpit connect those decisions to resources and performance.

The launch decision architecture
  1. The Spine — headquartersA shared franchise story, segmentation logic, readiness gates, KPI architecture, decision rights and compliance floor.
  2. The Choice — country teamsChoose and document the engagement model that fits the market: KOL-Led Specialist, Omnichannel Hybrid, Foundation Build or Digital-First.
  3. The Cycle — adaptationAgree leading indicators, thresholds and the operational change that follows when a threshold is crossed.
  4. The Glue — governanceA Launch Council with decision-making authority and a Launch Cockpit using shared definitions.

Adapted from the framework in the paper. The layers work together; they are not a sequence of project phases.

Evidence and method

The Launch Reality analysis selects 50 launches using pre-launch analyst attention and expected peak sales. Dated, pre-approval analyst or company forecasts are compared with company-reported sales through 2025. Four COVID products are kept separate because pandemic demand makes them atypical. Five launches were too early to judge. The accompanying spreadsheet makes the underlying comparisons available for scrutiny.

How to interpret this

This is a selected retrospective sample, not a random sample or a causal experiment. Being below a projected peak is not the same as a mature launch missing its forecast: products have different time on market. The framework structures judgement rather than replacing it; country scores reflect a moment in time, and resource allocation remains a separate decision.

Source: The Launch Decision Architecture, with the Launch Reality Report and supporting dataset. The complete paper contains the supporting detail and references.

Read the full paper

Download the complete whitepaper and explore the analysis in detail.

Download the PDF

Launch Reality Report

Supporting dataset

Pieter Vanderbeeken

Pieter works with life sciences teams on customer experience, commercial excellence, segmentation and omnichannel. He previously built and led the Asia-Pacific business of Across Health and Precision AQ. At Fractal Force, he leads delivery and business development. Pieter on LinkedIn

Mark Watson

Mark has worked in healthcare since 2012. He was EMEA omnichannel manager at Janssen and head of strategy at Across Health and Precision AQ. At Fractal Force, he leads client relationships and develops the methods used in our engagements. Mark on LinkedIn

A conversation is a good place to start

Talk through your customer engagement challenge

Book 30 minutes with us to discuss what to change and where to start.

Let’s talk

Book a conversation